Cancer Cachexia Global Clinical Trials Review, H1, 2012

2012-02-20
Published : Feb-2012

GlobalData’s clinical trial report, “Cancer Cachexia Global Clinical Trials Review, H1, 2012″ provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Cachexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Cancer Cachexia Clinical Trials

Published: February 2012
No. of Pages: 76
Price: US$1000

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5

Introduction 6
Cancer Cachexia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Clinical Trials by BRIC Nations 13
Clinical Trials by G7 Nations 14
Clinical Trials in G7 Nations by Trial Status 15
Clinical Trials by E7 Nations 16
Clinical Trials in E7 Nations by Trial Status 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Subjects Recruited Over a Period of Time 21
Prominent Sponsors 22
Top Companies Participating in Cancer Cachexia Therapeutics Clinical Trials 24
Prominent Drug Comparison 26
Clinical Trial Profiles 27
Clinical Trial Overview of Top Companies 27
Helsinn Healthcare S.A. 27
Clinical Trial Overview of Helsinn Healthcare S.A. 27
PsiOxus Therapeutics, Ltd. 28
Clinical Trial Overview of PsiOxus Therapeutics, Ltd. 28
Acacia Pharma Ltd. 29
Clinical Trial Overview of Acacia Pharma Ltd. 29
Ohr Pharmaceutical Inc. 30
Clinical Trial Overview of Ohr Pharmaceutical Inc. 30
Alder Biopharmaceuticals Inc. 31
Clinical Trial Overview of Alder Biopharmaceuticals Inc. 31
Pfizer Inc. 32
Clinical Trial Overview of Pfizer Inc. 32
GTx, Inc. 33
Clinical Trial Overview of GTx, Inc. 33
Ark Therapeutics Group plc 34
Clinical Trial Overview of Ark Therapeutics Group plc 34
Bristol-Myers Squibb Company 35
Clinical Trial Overview of Bristol-Myers Squibb Company 35
Clinical Trial Overview of Top Universities / Institutes / Hospitals 36
Baylor College of Medicine 36
Clinical Trial Overview of Baylor College of Medicine 36
Cantonal Hospital of St. Gallen 37
Clinical Trial Overview of Cantonal Hospital of St. Gallen 37
VU University Medical Center 38
Clinical Trial Overview of VU University Medical Center 38
Case Comprehensive Cancer Center 39
Clinical Trial Overview of Case Comprehensive Cancer Center 39
University Hospital Freiburg 40
Clinical Trial Overview of University Hospital Freiburg 40
H. Lee Moffitt Cancer Center & Research Institute 41
Clinical Trial Overview of H. Lee Moffitt Cancer Center & Research Institute 41
Five Key Clinical Profiles 42

Appendix 73
Abbreviations 73
Definitions 73
Research Methodology 74
Secondary Research 74
About GlobalData 75
Contact Us 75
Disclaimer 75
Source 76

List of Tables

List of Figures

Filed in: Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

“The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......
$4950

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases,  growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders,  rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on  product in 2021.” Based on products, the topical drug delivery the market is segmented into ......
$4950

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

“Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......
$4950

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027

The global Healthcare cloud computing market is projected to reach USD 89.4  billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......
$4950

Digital Pathology Market by Product (ArtificiaI Intelligence, Scanner, Software, Storage), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma, Academia, Hospitals) – Global Forecast to 2026

“The Digital Pathology market is projected to grow at a CAGR of 13.2% during the forecast period (2021–2026).” The global digital pathology market is projected to reach USD 1,371 million by 2026 from USD 736 million in 2021, at a CAGR of 13.2% during the forecast period. The growth in the digital pathology market is mainly driven by factors such as the increasing adoption of digital pathology to enhance lab efficiency, rising incidence of cancer, and growing applications of digital pathology in drug development and companion diagnostics. On the other hand, the high costs of digital pathology systems are expected to restrain market growth to a certain extent. “The scanners segment accounted for the largest share of the Digital Pathology market in 2020.” Based on products,......
$4950

Telehealth & Telemedicine Market by Component (Software & Services (RPM, Real-Time), Hardware (Monitors)), Delivery (On-Premise, Cloud-Based), Application (Teleradiology, Telestroke, TeleICU), End User (Provider, Payer) & Region – Global Forecasts to 2027

“The telehealth & telemedicine market is projected to grow at a CAGR of 26.6% during the forecast period (2022–2027).” The global telehealth & telemedicine market is expected to grow at a CAGR of 26.6% during the forecast period, to reach USD 285.7 billion by 2027 from an estimated USD 87.8 billion in 2022.The key factors driving the growth of this market include the need to expand healthcare access, the growing prevalence of chronic diseases and conditions, a shortage of physicians, advancements in telecommunications, government support and raising awareness, and rising technology adoption in the wake of COVID-19. However, regional variations in regulations, fraud, and the use of social media for care providers will restrict the market growth during the forecast period. ......
$4950

Teleradiology Market by Product & Service (Services, Hardware, Software (PACS, RIS)), Imaging Technique (MRI, CT, X-ray, Ultrasound, Mammography, Nuclear Imaging), End User (Hospitals, Diagnostic Centers& Laboratories), COVID-19 Impact – Forecast to 2026

“A shortage of skilled radiologists & need for faster and improved diagnosis are driving market growth” The teleradiology market is expected to reach USD 14.8billion by 2026 from USD 7.3 billion in 2021, at a CAGR of 15.3% during the forecast period of 2021 to 2026. Due to the outbreak of coronavirus globally, there is a sudden rise in the demand for teleradiology services. The growth of this market is mainly attributed to the growth of the teleradiology market is driven by the rising geriatric population and the subsequent increase in the prevalence of associated diseases; the increasing number of advanced imaging procedures and a shortage of skilled radiologists; advancements in teleradiology the increasing adoption of cloud-based solutions. However, declining reimbursements a......
$4950

Healthcare Consulting Services Market by Type of Service (Digital Health, IT, Operations, Strategy, Financial, HR & Talent), End User (Government Bodies, Healthcare Providers, Pharmaceutical & Biotechnology Companies), and Region – Global Forecasts to 2026

Global healthcare consulting services market is projected to grow at CAGR of 11.5%” The global healthcare consulting services market is projected to reach USD 41.2 billion by 2026 from USD 23.9 billion in 2021, at a CAGR of 11.5% during the forecast period. Healthcare consulting firms specialize in providing business consulting services to the healthcare industry in areas such as finance, accounting, marketing, insurance, healthcare management, billing, coding, regulations & compliance, healthcare standards, and many other similar areas. Growth in the healthcare consulting services market can be primarily attributed to the growing budget cuts, increasing pricing pressure, changing healthcare policies/regulations, and rising technological disruption across the healthcare industry t......
$4950

Animal Growth Promoters and Performance Enhancers Market by Type (Antibiotic and Non-antibiotic (Hormones, Acidifiers, Feed Enzymes, Probiotics & Prebiotics, Phytogenic)), Animal Type (Poultry, Porcine, Livestock, Aquaculture) – Global Forecast to 2026

“The global animal growth promoters and performance enhancers market is projected to grow at a CAGR of 5.7%” The global animal growth promoters and performance enhancers market is projected to reach USD 21.4 billion by 2026 from USD 16.2 billion in 2021, at a CAGR of 5.7%. Animal health products, including growth promoters and performance enhancers, are types of drugs and chemicals used for animal growth. These enhancers help to digest food more effectively and enable animals to grow faster, which, in turn, help to improve productivity. Growth in the animal growth promoters and performance enhancers market is majorly driven by the rising demand for animal consumption and consumption of livestock-based products, rising global demand for naturally produced growth promoters, and rising......
$4950

Hemophilia A and B – Epidemiology Forecast to 2030

Hemophilia A and B - Epidemiology Forecast to 2030 Summary Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation because of deficiencies in the production or function of coagulation factor VIII in hemophilia A or factor IX in hemophilia B (Bolton-Maggs and Pasi, 2003). Because of the deficiency of coagulation factor, hemophilia patients have a tendency to bleed in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease (CDC, 2021; Mayo Clinic, 2021). According to the World Federation of Hemophilia (WFH), hemophilia is rare. About 1 in 10,000 people are born with hemophilia A and about 1 in 50,000 people are born with hemophilia B......
$3995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy